USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
Elon Musk’s Unusual Relationships With Women at SpaceX
New York’s U-Turn on a Plan to Reduce Traffic
Shein: Fast Fashion, Slow IPO
Trillion Dollar Shot, Episode 4: The Disruptors
‘It Came out of Nowhere’: The Rise of Dr Pepper
Why Biden Is Cracking Down on Asylum at the Border
Behind Closed Doors, Biden’s Age is Showing
A Conversation with Alphabet’s Captain of Moonshots
Mexico Has a New President. Will She Be Different?
Trillion Dollar Shot, Episode 3: Brad
The Origin Story of Trump's Guilty Verdict
The Big Short: China Edition
The Trustbuster Taking on Ticketmaster
$2.8 Billion for College Athletes and a New World for the NCAA
Introducing Science Vs - Ozempic: Is It Scarier Than We Thought?
The First Person to Get Elon Musk’s Neuralink Brain Chip
Could Paris Hilton Create the 'Next Disney?'
Years After Surfside Collapse, Florida Condos Are In Crisis
Why Israel and Hamas Could Be Headed Into a Forever War
Did ‘Roaring Kitty’ Just Spark a Meme Stock Sequel?
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained